NDAOPHTHALMICOINTMENT
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 7h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CHLOROMYXIN is a fixed-dose ophthalmic ointment combining chloramphenicol and polymyxin B sulfate, two broad-spectrum antibiotics indicated for bacterial eye infections. The combination provides synergistic antimicrobial coverage against gram-positive and gram-negative organisms. This product targets patients with infectious conjunctivitis, blepharitis, and other external ocular infections.
Pre-Launch
Pre-launch stage indicates commercial infrastructure is being built; expect significant hiring for field teams, marketing, and launch operations.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CHLOROMYXIN at pre-launch offers entry or growth opportunities in ophthalmology, particularly for launch-phase roles in a Pfizer specialty care environment. This is a career-building opportunity if you want hands-on launch experience, but assess long-term growth given the mature competitive landscape and generic pressure typical in ophthalmic antibiotics.
Brand Manager
Worked on CHLOROMYXIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.